PETALUMA, Calif., Dec. 24, 2012 (GLOBE NEWSWIRE) -- Oculus Innovative Sciences, Inc. (Nasdaq:OCLS) a healthcare company that designs, produces and markets innovative, safe and effective anti-infective products and medical devices while also developing multiple drug candidates, today announced that a pending reclassification of the company's CE Mark for the European formulation Dermacyn™ Wound Care for the European market is expected by year's end. The reclassification is under the review of the British Standards Institution (BSI), which is the world's largest certification body, and the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom. Reclassified as a class III medical device, the newest indication would include "possible local antimicrobial effect in the wound bed." "We are pleased with the expanded label indication as it will help increase sales for our existing sales partners in Europe and secondly, increases our chances of licensing our anti-infective drug product to prospective European partners focused on the surgical suite," said Hoji Alimi, Oculus founder and CEO. "As evidenced by our effective collaborative efforts with partners in the United States and Mexico, our partnership strategy has facilitated a sustainable rapid sales ramp while minimizing expenses since our partners underwrite the costs associated with marketing and sales." About Oculus Innovative Sciences Oculus Innovative Sciences is a healthcare company that designs, produces and markets innovative, safe and effective anti-infective products and medical devices while also developing multiple drug candidates for various indications including treatment of acne and surgical suite use. Oculus is pioneering innovative solutions in multiple markets for the dermatology, surgical, wound care, and animal healthcare markets, and has commercialized products in the United States, Europe, India, China, Mexico and select Middle East countries. The company's headquarters are in Petaluma, California, with manufacturing operations in the United States and Latin America. More information can be found at www.oculusis.com . Oculus press releases contain information about products, which may or may not be available in any particular country, and if applicable, may have received approval or market clearance by a governmental regulatory body for different indications and restrictions in different countries. Each country has specific laws, regulations and medical practices governing the communication of medical or other information about medical products. Nothing herein should be construed as a solicitation or promotion for any product or for an indication for any product, which is not authorized by the laws and regulations of the country where the reader resides.